Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343365 · ClinicalTrials.gov registry record
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
A clinical trial of Incurable Disease, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 35
- Enrollment target
- 1
- Study location
NCT04343365: Recruiting study of Incurable Disease, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT04343365 is a study of Incurable Disease that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04343365, a study of Incurable Disease, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
Primary Outcome
The investigators want to demonstrate the ability of a multidisciplinary group, the ETB, to develop therapeutic strategies in participants without curative options. They plan to enroll 35 patients to this study over 3 years. The primary objective will be successfully met if they can develop an evolutionary based plan that differs from the participants options prior to presentation for at least 80%, or 28 of these participants.
Conditions Studied
Interventions
- OTHER Evolutionary Tumor Board (ETB)
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2028-03 |
What NCT04343365 shows while recruiting
NCT04343365 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 1 condition, with Incurable Disease appearing as the primary indexed condition, and to 1 intervention - of which Evolutionary Tumor Board (ETB) is the first listed.
NCT04343365 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04343365 about?
NCT04343365 is a clinical study titled "Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board". This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.
What is the current status of trial NCT04343365?
This trial is currently recruiting. The enrollment target is 35 participants. The study started on 2020-05-05. Estimated completion is 2028-03.
What conditions does trial NCT04343365 study?
This clinical trial studies the following conditions: Incurable Disease.
What interventions are being tested in trial NCT04343365?
The interventions under investigation include: Evolutionary Tumor Board (ETB) (OTHER).
Who is sponsoring clinical trial NCT04343365?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04343365 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI